– With a compact all-in-one wearable and a completely redesigned mobile app, the world’s best-selling real-time continuous glucose monitoring system is now more powerful and easier to use.
– The new system features market-leading fast sensor warm-up, eliminating the need for fingertip phlebotomy or scanning.
– Dexcom G7 builds on the trusted performance of Dexcom CGM, a clinically proven device that lowers glycated hemoglobin (A1C), reduces hyperglycemia and hypoglycemia, and increases blood sugar plateau time.
DexCom, the global leader in real-time continuous glucose monitoring for patients with diabetes, today announced that its Dexcom G7 continuous glucose monitoring (CGM) system has received CE marking for use in Europe for people with diabetes two years of age and older, including pregnant women .
The Dexcom G7 helps users better control their diabetes in a better way, allowing them to manage their condition more confidently every day. Its small, all-in-one wearable device has a faster warm-up time than any other CGM on the market, and automatically sends real-time blood glucose readings to compatible smart devices or receivers, eliminating the need for fingertip blood sampling. The Dexcom G7 also offers a suite of customizable alert features that warn you of high or low blood sugar and help users keep blood sugar levels steady for longer. Additionally, industry-leading remote monitoring and reporting capabilities enable users to stay connected with loved ones and care teams anytime, anywhere.
“Today is an incredible milestone for our company and for people with diabetes in Europe,” said Kevin Sayer, Chairman, President and CEO of Dexcom. “This new platform provides an exceptionally powerful, easy-to-use continuous glucose monitoring system that provides users with insightful blood sugar data on a single screen, helping them spend less time managing their diabetes and more time doing the things they love. The Dexcom G7 inherits all the well-received features of the G6, and make it even better.”
Dexcom G7 inherits the features of Dexcom G6:
– No fingertip blood sampling, scanning or calibration required
– Real-time blood glucose readings are automatically sent to compatible display devices
– Children 2 years and older can be worn on the upper arm and abdomen, children 2 to 17 years old can be worn on the upper buttocks
– Integration with the world’s largest connected CGM ecosystem
– Remote monitoring that enables users to share blood glucose data with up to 10 followers||
– Dexcom proven accuracy and performance
Dexcom G7 New Features:
– Developed in partnership with Verily, a 60% smaller, all-in-one wearable device
– 30 minutes sensor warm-up time, the best of any CGM on the market
– 12-hour grace period for replacing spent sensors for smoother transitions between measurements
– Redesigned and simplified mobile app that integrates with Dexcom Clarity
– Improved alarm settings with more intimate functions
– Redesigned optional receiver with a smaller size and a more visible display that is easier to read
– Directly connect to Apple Watch (related software is expected to be released in the future)
Additionally, Dexcom is working closely with insulin pump partners to integrate the Dexcom G7 into current and future automated insulin delivery systems as soon as possible.
Professor Partha S. Kar, National Specialist Adviser on Diabetes in the NHS England, Endocrinologist Adviser at Portsmouth Hospitals NHS Trust, and Officer of the Order of Merit, said: “Over the past 20 years, Dexcom has Has been one of the leaders and pioneers in advancing real-time CGM technology. Dexcom G7’s enhanced functionality and ease of use promise to make diabetes management easier for patients and healthcare facilities, which is especially important. We observe that more and more There is more evidence that CGM can benefit more people with diabetes.”
Dexcom expects to kick off the Dexcom G7 launch event in Europe in the coming weeks. The company also plans to introduce an upgraded CGM algorithm in 2022 that will take the performance of CGM sensors to the next level.
About DexCom
Dexcom helps people manage their diabetes with an innovative continuous glucose monitoring (CGM) system. Headquartered in San Diego, California, with operations throughout Europe, the company has grown into a leader in diabetes care technology. By listening to the needs of users, caregivers, and healthcare organizations, Dexcom simplifies and improves diabetes management around the world.
